Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta-agonists (LABA) for adults with asthma.

Rating:
4 out of 5 stars

The Evidence Summary for this article has been prepared by the Cochrane Collaboration-a highly reputable, global, independent network of researchers, professionals, patients, carers and people interested in health.

You can click on 'Cochrane Summary,' which will open a new window on your screen and display the summary.
Cochrane Summary
You can view a one-page summary written for Professionals. View Clinician article

Browse topics
Evidence Summaries
Web Resource Ratings
Blog Posts
Patient Decision Aid
Professional
Clinician
Public Health Professional
Policymaker (health systems)

Register for free access to all Professional content

+AA

Evidence Summary

What is an Evidence Summary?

Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta-agonists (LABA) for adults with asthma.

Register for free access to all Professional content

Our Content

About

Full Article

Evidence Summary

What is an Evidence Summary?

Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta-agonists (LABA) for adults with asthma.

Register for free access to all Professional content